Clinical trials: Pegfilgrastim
Hematological Neoplasms, Tumors
Pegfilgrastim Versus Filgrastim After High-dose Chemotherapy
The primary objective of the study is to evaluate the efficacy and the safety of pegfilgrastim versus filgrastim, administered after high-dose chemotherapy and peripheral stem cell reinfusion.
- Trial name
- NCT00410696
- Testing
- Filgrastim, Pegfilgrastim
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- Armando Santoro, MD
Breast Cancer
PEG-rhG-CSF in Patients With Breast Cancer Receiving Chemotherapy to Prevent Neutropenia
The purpose of this study is to estimate the efficacy and safety of PEG-rhG-CSF in patients with breast cancer receiving chemotherapy.
- Trial name
- NCT02805205
- Testing
- PEG-rhG-CSF
- Volunteers
- 484 people
- Sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Bladder Cancer
Stress-reducing Intervention in Urothelial Carcinoma
The aim of this interventional study is to test the heart-rate variability biofeedback intervention (HRV BI) in patients with muscle-infiltrating bladder carcinoma (MIBC) treated with chemotherapy based on cisplatin in…
- Trial name
- NCT06269536
- Testing
- HRV biofeedback
- Where
- Slovakia
- Volunteers
- 50 people
- Sponsor
- Comenius University
Healthy Volunteers
Study Comparing TPI-120 and Neulasta Administered Through Subcutaneous Route in Healthy Adult Subjects
This is a single or up to 2 centers, double-blind, randomized, single-dose, two-way, crossover study comparing the Test (T) and Reference (R) products following subcutaneous administration.
- Trial name
- TPI-120 (NCT03206229)
- Testing
- PEG-rhG-CSF, Neulasta (PEG-rhG-CSF)
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Adello Biologics, LLC
Lymphoma
the Efficacy and Safety of PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells in Lymphoma
A single center, non-inferiority, two-way cohort clinical study to evaluate the efficacy and safety of pegylated recombinant human granulocyte stimulating factor injection in the mobilization of autologous hematopoietic stem…
- Trial name
- NCT05834751
- Testing
- PEG-rhG-CSF, RhG-CSF
- Where
- China
- Volunteers
- 144 people
- Sponsor
- Ou Bai, MD/PHD
Osteosarcoma, Lung Metastases
A Study of Pre-Operative Treatment of Newly-Diagnosed, Surgically-Resectable Osteosarcoma With Doxorubicin, Ifosfamide, Etoposide, and Cisplatin With Early Metabolic Assessment of Response
This is a pilot study that will allow investigators to collect data related to early and potentially more accurate response assessments using a chemotherapy protocol that eliminates methotrexate to maximize the dose intensity of…
- Trial name
- NCT01258634
- Testing
- Dexrazoxane, Doxorubicin, Cisplatin
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Chicago
Breast Cancer
Dose Density FU 75 and FU 90 as Adjuvant Therapy for Early Breast Cancer
This is an open -label randomized phase II study of dose-dense Fluorouracil/Epirubicin/Cyclophosphamide (FEC) administered with Epirubicin of 75mg/m2 (FEC75) and Epirubicin 90mg/m2 (FEC90) in untreated patients with early breast…
- Trial name
- NCT00286819
- Testing
- the FEC75 and 95 regimen
- Where
- 5 sites in Austria, Hungary and 2 more
- Volunteers
- 50 people
- Sponsor
- Central European Cooperative Oncology Group
Burkitt's Lymphoma, Burkitt'S-like Lymphoma
Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma
The goal of this clinical research study is to learn if intensive chemotherapy given over 6 months can help to control or cure Burkitt's leukemia, Burkitt's lymphoma, or small non-cleaved cell B-cell leukemia or lymphoma.
- Trial name
- NCT00669877
- Testing
- Rituximab, Cyclophosphamide, Doxorubicin
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia
Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia
Any time the words "you," "your," "I," or "me" appear, it is meant to apply to the potential participant. The goal of this clinical research study is to learn if intensive chemotherapy (hyper-CVAD therapy) given in combination…
- Trial name
- NCT01319981
- Testing
- Rituximab, Imatinib, Cyclophosphamide
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- M.D. Anderson Cancer Center
Medulloblastoma
Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma
This is a multi-center, multinational phase 2 trial that aims to explore the use of molecular and clinical risk-directed therapy in treatment of children 0-4.99 years of age with newly diagnosed medulloblastoma.
- Trial name
- NCT05535166
- Testing
- Surgical resection, Ommaya/VPS, Methotrexate
- Where
- 10 sites in United States
- Volunteers
- 130 people
- Sponsor
- St. Jude Children's Research Hospital
Grade 3b Follicular Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma
Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma
This phase I trial studies the best dose of copanlisib when given together with combination chemotherapy (R-GCD) in treating patients with diffuse large B-cell lymphoma that has come back (relapsed) or does not respond to…
- Conditions
- Grade 3b Follicular Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
- Trial name
- NCT04156828
- Testing
- Copanlisib, Gemcitabine, Carboplatin
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Washington
Sarcoma
Gemcitabine and Docetaxel in Treating Patients With Recurrent Osteosarcoma (Closed to Accrual as of 12/21/06) or Ewing's Sarcoma or Unresectable or Locally Recurrent Chondrosarcoma
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and docetaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining gemcitabine with docetaxel may kill more tumor cells.
- Trial name
- NCT00073983
- Testing
- filgrastim, pegfilgrastim, docetaxel
- Volunteers
- 54 people
- Sponsor
- Sarcoma Alliance for Research through Collaboration
Relapsed Neuroblastoma, Metastatic Pheochromocytoma
131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Relapsed/Refractory Neuroblastoma
This expanded access is the best available therapy/compassionate use designed to determine the palliative benefit and toxicity of 131I-MIBG in patients with relapsed/refractory neuroblastoma or metastatic pheochromocytoma who are…
- Trial name
- NCT03649438
- Testing
- 131 I-Metaiodobenzylguanidine, Potassium Iodide, G-csf
- Where
- United States
- Sponsor
- University of Texas Southwestern Medical Center
Non-Hodgkin's Lymphoma
A Study of Peripheral Blood Progenitor Cell (PBPC) Mobilisation by Chemotherapy With Pegfilgrastim or Filgrastim in Subjects With Non-Hodgkin's Lymphoma
The purpose of this study is to evaluate the ability of two different fixed doses of pegfilgrastim (6mg and 12mg) and a by-weight dose of filgrastim (5ug/kg/day) for the mobilisation and collection of PBPCs for autologous…
- Trial name
- NCT00117455
- Testing
- pegfilgrastim, filgrastim
- Sponsor
- Amgen
Ewing Family of Tumors, Rhabdomyosarcoma
PK/PD of XM22 in Children With Ewing Family of Tumors or Rhabdomyosarcoma
This is a Phase I, open label study aimed at assessing the pharmacokinetics, pharmacodynamics, the efficacy, safety, and tolerability of a single injection of XM22 in children with Ewing family of tumors or rhabdomyosarcoma…
- Trial name
- NCT01585649
- Testing
- Lipegfilgrastim
- Where
- 18 sites in Bulgaria, Czechia and 4 more
- Volunteers
- 21 people
- Sponsor
- Merckle GmbH
Adult Solid Neoplasm
Tivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors
This phase I trial studies the side effects and best dose of tivantinib and topotecan hydrochloride in treating patients with advanced or metastatic solid tumors.
- Trial name
- NCT01654965
- Testing
- Laboratory Biomarker Analysis, Pegfilgrastim, Pharmacological Study
- Where
- 7 sites in United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Febrile Neutropenia, Non-myeloid Malignancy
An Analysis to Estimate Febrile Neutropenia (FN) in Patients Receiving Udenyca
This is a multicenter, prospective, observational cohort registry in subjects receiving myelosuppressive chemotherapy for a non-myeloid malignancy who are considered to be at high risk for developing febrile neutropenia (FN).
- Trial name
- POEM (NCT04662892)
- Testing
- Pegfilgrastim-Cbqv
- Where
- 3 sites in United States
- Volunteers
- 200 people
- Sponsor
- Coherus Oncology, Inc.
Philadelphia Chromosome Negative, Recurrent B Acute Lymphoblastic Leukemia
Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia
This phase II trial studies how well low-intensity chemotherapy and blinatumomab work in treating patients with Philadelphia chromosome negative acute lymphoblastic leukemia that has come back or does not respond to treatment.
- Conditions
- Philadelphia Chromosome Negative, Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia
- Trial name
- NCT03518112
- Testing
- Blinatumomab, Cyclophosphamide, Cytarabine
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphoma
Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00101010
- Testing
- Filgrastim, Pegfilgrastim, Rituximab
- Where
- 7 sites in United States
- Volunteers
- 80 people
- Sponsor
- M.D. Anderson Cancer Center
Neutropenia, Severe Chronic
ANF-Rho in the Treatment of Chronic Neutropenia
A 6 month safety, tolerability, efficacy and pharmacokinetic study with ANF-Rho to treat patients with chronic neutropenia.
- Trial name
- NCT02533362
- Testing
- ANF-Rho
- Sponsor
- Prolong Pharmaceuticals